Skip to content

Efficacy and neurological mechanisms of repetitive transcranial magnetic stimulation on persistent erythema and flushing in patients with rosacea

Efficacy and neurological mechanisms of repetitive transcranial magnetic stimulation on persistent erythema and flushing in patients with rosacea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094108
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-12-18
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with Rosacea diagnosed according to Rosacea Treatment Guidelines (2017 edition).Diagnosis confirmed by two senior dermatologists; history of disease longer than 1 year (2) CEA score >= 1 and/or GFSS score >= 4; (3) not taking systemic therapeutic drugs (e.g. carvedilol, paroxetine, isotretinoin, etc.) within 4 weeks prior to study entry (4) Age 18 to 65 years; (5) Patients volunteered to participate in the study and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: (1) Serious systemic diseases (including cardiac and cerebrovascular diseases, thyroid diseases, liver and kidney dysfunction, etc.) (2) Other serious skin diseases (seborrheic dermatitis, systemic lupus erythematosus, dermatomyositis, etc.) (3) Serious mental disorders (e.g. schizophrenia, bipolar disorder) (4) Pregnant or breastfeeding women, or planning to have a pregnancy in the last 3 months (5) Previous transcranial magnetic therapy (6) Contraindications to magnetic resonance examination, such as metal implants in the body, claustrophobia, etc. (7) Presence of moderately severe rhinorrhea changes (8) Contraindications to TMS, e.g. epilepsy, cerebral haemorrhage, pacemaker, etc. (9) Other people who cannot cooperate with the completion of the TMS treatment operation.

Design outcomes

Primary

MeasureTime frame
Global flushing severity scale;

Secondary

MeasureTime frame
Clinican's Erythema Assessment;Patient's Self Assessment;Investigator's Global Assessment;Rosacea Area and Severity Index;Amplitude of Low Frequency Fluctuations;Reho;Functional connection;Brain network;Dermatology Life Quality Index;RosaQoL;Hospital Anxiety and Depression Scale;Pittsburgh Sleep Quality Index;

Countries

China

Contacts

Public ContactXian Jiang

West China Hospital, Sichuan University

jiangxian@scu.cn+86 177 5494 4718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026